Limei Wan

Limei Wan

Auto-generated profile, based on publicly available information

Limei Wan

The First Affiliated Hospital of Guangdong Pharmaceutical University 510080 Guangzhou China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
LWLimei Wan
Limei Wan
WWWeibin WU
Weibin WU
SJShunjun Jiang
Shunjun Jiang
SWShan he Wan
Shan he Wan
DMDongmei Meng
Dongmei Meng
PYPengjiu Yu
Pengjiu Yu
Recent studies have illuminated that blocking Ca2+ influx into effector cells is an attractive therapeutic strategy for lung injury. We hypothesize that T-type calcium channel may be a potential therapeutic target for acute lung injury (ALI). In this study, the pharmacological activity of mibefradil (a classical T-type calcium channel inhibitor) was assessed in a mouse model of lipopolysaccharide- (LPS-) induced ALI. In LPS challenged mice, mibefradil (20 and 40 mg/kg) dramatically decreased the total cell number, as well as the productions of TNF-α and IL-6 in bronchoalveolar lavage fluid (BALF). Mibefradil also suppressed total protein concentration in BALF, attenuated Evans blue extravasation, MPO activity, and NF-κB activation in lung tissue. Furthermore, flunarizine, a widely prescripted antimigraine agent with potent inhibition on T-type channel, was also found to protect mice against lung injury. These data demonstrated that T-type calcium channel inhibitors may be beneficial for treating acute lung injury. The important role of T-type calcium channel in the acute lung injury is encouraged to be further investigated.